America's Best Nonprofits
  1. Home
  2. Science & Technology
  3. San Diego, CA
  4. J Craig Venter Institute

J Craig Venter Institute

J Craig Venter Institute has an America's Best Score of 54 out of 100, based on its 2024 Form 990, below the 60-point bar to be ranked.

  • San Diego, CA
  • Tax-exempt since 1995
  • EIN: 52-1842938
jcvi.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
54OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

J Craig Venter Institute is a 501(c)(3) organization, classified under Science & Technology (NTEE U50Z). Contributions are tax-deductible.

950 Waterfront Place, San Diego, CA 92101-6180

Among the 23 scored science & technology organizations in San Diego, J Craig Venter Institute holds 19.1 months of operating reserves (peer median 10.1 months), runs a typical yearly deficit of 30.7% (peers: deficit of 3.7%), and has cut spending 8.3% a year (peers: grown spending 14.8% a year).

In fiscal year 2024 it reported $14,407,483 in revenue and $19,604,869 in expenses, with contributions making up 89.4% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2024 Form 990

J. Craig venter institute (jcvi) is an independent 501(c)(3) Nonprofit organization advancing the science of genomics committed to accelerating foundational scientific research to drive advances in human health and environmental sustainability. This past year jcvi committed research efforts in human health, environmental sustainability, synthetic biology, and software tools and technology.

Largest programs · fiscal year 2024

  • Department of health and human services: Two million people in the U.S. Are diagnosed annually with life-threatening infections caused by antibiotic resistant bacteria that are responsible for 35,000 deaths each year with an economic impact estimated to be as much as $20 billion a year in direct healthcare costs. Due to the spread of antibiotic resistance, very few drugs remain that can treat thes… Read more

    Department of health and human services: Two million people in the U.S. Are diagnosed annually with life-threatening infections caused by antibiotic resistant bacteria that are responsible for 35,000 deaths each year with an economic impact estimated to be as much as $20 billion a year in direct healthcare costs. Due to the spread of antibiotic resistance, very few drugs remain that can treat these infections. Led by derrick fouts, phd, (jcvi) and funded by the centers for disease control and prevention (cdc), the j. Craig venter institute and cleveland va prevention and intervention epicenter are developing novel interventions that will prevent the colonization and spread of antibiotic resistant (ar) bacteria that cause hospital acquired infections (hai), and to develop diagnostics and interventions to combat the colonization by the rapidly emerging fungal pathogen candida auris. Collaborators on this multi year funded center include research labs at duke university, case western university and northwestern university. Led by indresh singh, director of informatics, the jcvi is a key colloborator for the bacterial and viral bioinformatics resource center (bv-brc). Using the advanced system architecture based on high-performance computing, extensible database management approach structured on emerging metadata standards, and suite of analysis and visualization tools and services available for customized workflow assembly jcvi supports ongoing development of the comprehensive integrated bv-brc through a team of virology, immunology, bioinformatics, and information technology professionals who focus on the development, enhancement, and training of the bv-brc resource for the national institute of allergy and infectious diseases, their supported researchers, and the broader infectious disease research community. Infections caused by klebsiella pneumoniae are increasingly prevalent and difficult to treat due to ineffective treatment options due to increased antibiotic resistance. Bacteriophages, viruses that infect and kill bacteria, are being used to effectively treat and cure infections caused by a number of bacterial pathogens. To address the need for new treatments for wound and pulmonary infections caused by k. Pneumoniae, dr. Derrick fouts team has developed a 5-phage lead candidate therapeutic cocktail that is capable of infecting 53 of our 100-strain test panel. Funded by the national institute of allergy and infectious diseases, the jcvi, the walter reed army institute of research (wrair) and adaptive phage therapeutics (apt) will optimize the lead therapeutic and its production as well as conduct the required preinvestigational new drug (ind) testing and benchmarking necessary for the successful submission and review of an ind application for a phase 1 clinical trial. Research will leverage jcvi's history of synthetic and phage genomics, wrair's experience developing phage therapeutics, development of mouse models, and apts cgmp production capabilities and experience with phage clinical trials.

    $5,271,780 spent · 59.1% of program spending
  • National science foundation continues to fund the j. Craig venter institute (jcvi) in the areas of synthetic biology, integrative organismal systems core programs. Funded by the office of international science and engineering, dr. Tae seok moon, jcvi professor leads an international consortium through a global center to address the challenges of recalcitrant waste streams by developing integrated,… Read more

    National science foundation continues to fund the j. Craig venter institute (jcvi) in the areas of synthetic biology, integrative organismal systems core programs. Funded by the office of international science and engineering, dr. Tae seok moon, jcvi professor leads an international consortium through a global center to address the challenges of recalcitrant waste streams by developing integrated, novel, and scalable processes for their valorization, integrating researchers all over the world and from academia and industry, and providing global education, outreach activities, and workforce. Global centers: Circle: Center for innovative recycling and circular economy is suported by research teams in the united states, canada, united kingdom, korea, japan, singapore & australia. This center will develop three core technologies, including (1) Multi-omics-based bioprospecting to discover new enzymes, gene regulators, and organisms for waste valorization, (2) Predictive computational approaches to enable forward engineering of proteins and strains for biomanufacturing, and (3) Tea, lca, and risk assessment to develop commercially viable bioprocesses for waste valorization. To demonstrate the utility and generalizability of the developed core technologies, we will develop commercially viable valorization processes for three waste streams, including mixed plastics, c1 gases, and biogenic wastes (e.g., food, agricultural, and paper/cardboard wastes). If successful, these high-risk, high-return center projects will provide novel waste conversion processes that can be considered for commercial-scale, sustainable bioproduction. This is multi-year international study. The us consortium has been funded upto $4.9m. Non-us collaborators have been funded through research agencies within their own countries. Under the division of molecular and cellular bioscience and in collaboration with the university of Illinois minimal bacterial cell computational modeleing team led by zaida luthey-schulten, jcvi researchers led by dr. John glass, are carrying out transcriptome and metablomic analyses, biochemical and genetic experiements to discover unknown gene functions, optimization of a minimal cell defined growth medium, and constrcution of minimal cell mutatns to facilitate the work of jcvi and other group[s investigating minimal cell biology. This is a multi-year study with collaborative funding of $2.0m (~$0.7m jcvi).led by dr. John glass, the jcvi is investigating the mechanism of genome transplantation, develop genome transplantation for at least two species of non-mycoplasma bacteria, and use microfluidics technology to automate and improve the efficiency of genome transplantation. Genome transplantation, the insertion of a complete bacterial genome into a suitable recipient cell so that the donated genome commandeers the recipient cell to produce a new cell with the genotype and phenotype of the donated genome, was the fundamental technical development that enabled the construction of the first bacterium with a synthetic genome. At the announcement of the creation of the world's first synthetic cell, jcvi-syn1.0, the work was heralded as a major accomplishment for humankind. To date, genome transplantation has only been achieved using a small subset if the atypical bacteria called mycoplasmas. This is a multi-year study with collaborative funding of $1.0m.

    $1,128,103 spent · 12.6% of program spending
  • Jcvi scientists have partnered with other scientists from leading academic centers to come together to answer key questions about the root cause of long COVID whether fragments of the coronavirus persist in the tissues of patients. The long COVID research inititative bands together scientsits from harvard unibversity, stanford university, the university of California, san francisco, yale universit… Read more

    Jcvi scientists have partnered with other scientists from leading academic centers to come together to answer key questions about the root cause of long COVID whether fragments of the coronavirus persist in the tissues of patients. The long COVID research inititative bands together scientsits from harvard unibversity, stanford university, the university of California, san francisco, yale university and the j. Craig venter institute. The inititative is backed by an inititial investment from the balvi, a scientifc investment fund. Jcvi funding is awarded through the polybio research foundation. Researchers are using advanced imaging and gene-sequencing techniques looking for evidence of the virus in tissues and analyzing its affect on the immune system. Over the last few years, advances in STEM cell research and synthetic biology have catalyzed an extraordinary expansion of organoid technology that is bringing changes to translational medicine, pharmaceutical research, and strategies for treating various human pathologies. Using STEM cells, organoids have been developed for multiple organs including liver, intestine, kidney, brain, stomach, skin, ovary, and lung. Funded by the larry l hillblom foundation, dr. John glass is leading a consortium of researchers that propose to develop organoids that can serve as surrogates for beta cells, which are the cells in the human pancreas that control blood glucose levels by synthesizing insulin. Our goal is that these organoids, when implanted in type 1 diabetics, will result in a better treatment and better lives for those patients.

    $2,066,947 spent · 23.2% of program spending
  • Other related programs for support of development of key staff & internships. $451,688 spent · 5.1% of program spending

Where each dollar went · fiscal year 2024

Of every dollar it spent, 45¢ went to programs, 53¢ to management and 2¢ to fundraising.

  • Programs $8,918,518
  • Management $10,251,598
  • Fundraising $434,753

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score54 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves19.1 mo; 1.8 mo in cash13.3 / 25
Financial balance (median margin)−30.7%0 / 20
Transparency3 full 990s, latest TY202420 / 20
Program growth−8.3% / yr3.4 / 15
Track record31 years10 / 10
Debt load21.0% of assets7.8 / 10
Total54.4 → 54
Spending on programs
Not scored; America's Best needs 65%+
45%Below

Compared with San Diego peers

MeasureThis organizationPeer median
Operating reserves19.1 mo10.1 mo
Typical margin−30.7%−3.7%
Spending growth−8.3% / yr+14.8% / yr
Debt load21.0%11.9%

Peers: the 23 San Diego science & technology organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$14,407,483Fiscal year 20242022: $1,132,51220222023: $15,132,73920232024: $14,407,4832024
Expenses$19,604,869Fiscal year 20242022: $23,314,20720222023: $21,845,67420232024: $19,604,8692024
Total assets$39,462,295Fiscal year 20242022: $56,307,76720222023: $48,982,02820232024: $39,462,2952024
Total liabilities$8,297,989Fiscal year 20242022: $9,402,61520222023: $10,026,64720232024: $8,297,9892024
Fiscal year ending December 2024
Revenue$14,407,483
Expenses$19,604,869
Net income−$5,197,386
Net assets$31,164,306

Notable sources of revenue

Percent of total revenue
Contributions$12,879,736
Program services$0
Investment income$1,524,575
Other (net)$3,172

Assets / debt

Total assets$39,462,295
Total liabilities$8,297,989
Net assets$31,164,306

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$15,132,739
Expenses$21,845,674
Net income−$6,712,935
Net assets$38,955,381

Notable sources of revenue

Percent of total revenue
Contributions$15,104,824
Program services$0
Investment income$627,098
Other (net)−$599,183

Assets / debt

Total assets$48,982,028
Total liabilities$10,026,647
Net assets$38,955,381

Compensation

Officers and key employees$3,002,758
Share of expenses13.7%
Fiscal year ending December 2022
Revenue$1,132,512
Expenses$23,314,207
Net income−$22,181,695
Net assets$46,905,152

Notable sources of revenue

Percent of total revenue
Contributions$16,500,408
Program services$0
Investment income$726,080
Other (net)−$16,093,976

Assets / debt

Total assets$56,307,767
Total liabilities$9,402,615
Net assets$46,905,152

Compensation

Officers and key employees$2,774,325
Share of expenses11.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?